This site is intended for health professionals only
Newsletter
Hospital Healthcare Europe
Login
Twitter
Linkedin
Facebook
Select Language
English
French
German
Italian
Spanish
News
Views
Reviews & Research
Clinical
Cardiovascular
Dermatology
Gastroenterology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Sponsored
Events
News
Views
Reviews & Research
Clinical
Cardiovascular
Dermatology
Gastroenterology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Sponsored
Events
Home
>
Biosimilars
Biosimilars
EU shock as Health Commissioner takes control of pharma
Biosimilars: the long and winding road to clinical equivalence
Future prospects for similar biological medicinal products
Biosimilars under fire … but where is the justification?
Biosimilars: the need to tick all the right boxes
Biosimilars in the EU: the interplay of regulators, treating physicians and pharmacists
Quality and purity of biosimilar epoetin zeta (Retacrit®) readily demonstrated in drug product analysis
Sandoz receives European Commission approval for biosimilar filgrastim
Progress with biopharmaceuticals in Europe
First biosimilar approved for the treatment of neutropenia
One million pound boost for biomedical company
Sandoz receives positive EU opinion for biosimilar filgrastim
« Previous
1
…
4
5
6
7
8
Next »
Most read
1
Transcranial magnetic stimulation brain connectivity changes in major depression visible on MRI scan
by Rod Tucker
2
Oral vitamin A could become an alternative to isotretinoin for acne
by Rod Tucker
3
Amino acids supplement reduces muscle wasting and improves gut function in critically ill
by Rod Tucker
4
Less than two-thirds of patients alive 10 years after out-of-hospital cardiac arrest
by Rod Tucker
5
Launch of the new Hospital Pharmacy Europe Mobile App
by aporter2
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
x
Search for: